[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tartu University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":178},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,66,91,128,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100639532","risk-factors-for-hypoparathyroidism-following-thyroidectomy-100639532",false,"NCT07582562","Risk Factors for Hypoparathyroidism Following Thyroidectomy","A Prospective Study to Assess Risk Factors for Hypoparathyroidism Following Thyroidectomy","Inclusion Criteria:\n\n* patients over the age of 18 undergoing surgery involving both lobes of the thyroid gland (thyroidectomy, \"near-total\" thyroidectomy, subtotal thyroidectomy, and \"completed\" thyroidectomy)\n* patients who are capable of giving informed consent\n\nExclusion Criteria:\n\n* patients undergoing unilateral thyroid lobectomy only\n* patients with concomitant hyperparathyroidism undergoing simultaneous thyroidectomy and parathyroidectomy for a parathyroid adenoma","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to identify the risk factors for post-thyroidectomy hypoparathyroidism in Estonia and to determine whether the magnesium level plays a significant role in the development of hypoparathyroidism. The main questions it aims to answer are:\n\n* How common is post-thyroidectomy hypoparathyroidism in Estonia?\n* What are the most significant risk factors for the development of post-thyroidectomy hypoparathyroidism in Estonia?\n* Are magnesium levels a risk factor for the development of hypoparathyroidism? Participants will be asked to answer a questionnaire about risk factors. The study collects data on risk factors for hypoparathyroidism following thyroid surgery, including patient questionnaires and comorbidities, pre- and postoperative laboratory tests and surgery-related risk factors.",[24],"Post-Surgical Hypoparathyroidism",[26,27,28],"thyroidectomy","hypoparathyroidism","risk factors","RECRUITING","2026-05-05",{"date":32,"type":33},"2026-05-13","ACTUAL",{"date":35,"type":33},"2025-10-13",{"date":37,"type":20},"2028-12",{"name":39,"class":40},"Tartu University Hospital","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":65,"locationsCount":41},"100639834","calcium-replacement-therapy-in-postoperative-hypoparathyroidism-100639834","NCT07577570","Calcium Replacement Therapy in Postoperative Hypoparathyroidism","A Pilot Study of Calcium Replacement Therapy in Postoperative Hypoparathyroidism","Inclusion Criteria:\n\n* patients over the age of 18 undergoing surgery involving both lobes of the thyroid gland (thyroidectomy, \"near-total\" thyroidectomy, subtotal thyroidectomy, and \"completed\" thyroidectomy)\n* Based on the first post-operative day analysis, PTH levels are below the normal range (in our hospitals 1.8-7.8 pmol\u002Fl), but not so low (below 1.06 pmol\u002FL) as to require calcium replacement therapy with calcitriol (rocaltrol)\n\nExclusion Criteria:\n\n* previously diagnosed osteoporosis; the patient is already taking calcium and vitamin D supplements prior to thyroid surgery\n* renal insufficiency (eGFR \\\u003C 30)\n* patients with concomitant hyperparathyroidism undergoing simultaneous thyroidectomy and parathyroidectomy for a parathyroid adenoma",{"count":50,"type":20},50,"INTERVENTIONAL",[53],"NA","The goal of this clinical trial is to evaluate whether a lower-dose calcium replacement therapy is non-inferior to a higher-dose regimen in preventing symptomatic hypoparathyroidism in patients following thyroidectomy. The hypothesis is:\n\n• lower-dose calcium replacement therapy is non-inferior to higher-dose therapy in preventing symptomatic hypoparathyroidism during the first two postoperative weeks\n\nResearchers will compare patients receiving a lower-dose calcium replacement regimen with those receiving a higher-dose regimen to assess whether the lower dose is not associated with a higher incidence of symptomatic hypoparathyroidism.\n\nPatients who develop post-thyroidectomy hypoparathyroidism are divided into groups for calcium replacement therapy. If they are asymptomatic, they will be scheduled for a follow-up visit at two weeks after surgery. During the follow-up visit, calcium metabolism will be evaluated, and treatment adjusted if necessary.",[56],"Post-Thyroidectomy Hypoparathyroidism Treatment",[26,58,59],"calcium replacement therapy","postoperative hypoparathyroidism",{"date":61,"type":33},"2026-05-11",{"date":63,"type":33},"2025-11-18",{"date":37,"type":20},{"name":39,"class":40},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100532626","myocardial-dysfunction-evaluation-in-lower-extremity-arterial-disease-patients-with-deformation-analysis-100532626","NCT06215248","Myocardial Dysfunction Evaluation in Lower Extremity Arterial Disease Patients With Deformation Analysis","Assessment of Dysfunction in Left Cardiac Chambers With Strain-analyses in Patients With Lower Extremity Arterial Disease","MEDAL","Inclusion Criteria in LEAD group:\n\n* Fontaine I-IV class symptoms\n* Confirmed diagnosis of LEAD\n\nInclusion Criteria in control group:\n\n* Age 35-85\n* Has to have at least of the following: hypertension, diabetes, coronary artery disease or the patient smokes\n\nExclusion Criteria:\n\n* Age \\\u003C35 or \\>85 years\n* BMI ≥40 kg\u002Fm²\n* Known heart failure in history\n* Any acute or chronic autoimmune or rheumatic disease\n* Cardiac structural disease in history: inflammatory, infiltrative diseases, nonischemic cardiomyopathies\n* Acute coronary syndrome in last 3 months\n* Moderate to severe cardiac valvular disease\n* Cardiac valvular disease operative\u002Finvasive treatment in history\n* Cardiac implantable electronic device (CIED)\n* Transitory ischemic attack or stroke in last 3 months\n* Severe COPD (GOLD C or D)\n* Moderate to severe asthma (according to GINA 2022 criteria)\n* Untreated hypertension (noninvasive blood pressure measurement ≥180\u002F110 mmHg during recruitment)\n* Chronic severe kidney dysfunction (eGFR \\\u003C30 ml\u002Fmin\u002F1,73 m²)\n* Malignant tumor with radiation treatment to thorax, oncologic or biologic treatment in history\n* Chronic hematologic disease (except for anemia)\n* Severe liver dysfunction\n* Malignant tumor with \\\u003C5 years of remission\n* Acute or chronic infectious disease\n* Anemia with hemoglobin \\\u003C80 g\u002FL","35 Years","85 Years",{"count":77,"type":20},162,"Single centre observational study to assess lower extremity arterial disease (LEAD) patients' cardiac dysfunction with strain analyses and to assess connections between cardiac dysfunction, metabolomic changes and target organ damage in LEAD.",[80,81],"Peripheral Artery Disease","Heart Failure","2025-12-08",{"date":84,"type":33},"2025-12-16",{"date":86,"type":33},"2024-02-01",{"date":88,"type":20},"2026-12-31",{"name":39,"class":40},1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":51,"phases":102,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100517353","outcomes-of-massive-rotator-cuff-tendon-tear-treatment-100517353","NCT06016439","Outcomes of Massive Rotator Cuff Tendon Tear Treatment.","Outcomes of Different Treatment Modalities for Massive Rotator Cuff Tendon Tear.","Inclusion Criteria:\n\n* Massive rotator cuff tendon tear: grade III according to Davidson and Burkhart 2010 classification, diagnosed on MRI, and LHBB tendon is intact.\n* Primary rotator cuff pathology AND\n* Symptoms have not lasted more than 6 months.\n* In case of trauma, traumatic event no more than 6 months ago.\n* Aged between 50 and 80 at the time of enrollment.\n* Subject is able and willing to give informed consent AND\n* Subject is physically and mentally willing and able to comply with the post-operative rehabilitation protocol, questionnaires, and scheduled clinical and radiographic visits.\n\nExclusion Criteria:\n\n* Previous rotator cuff surgery of the index shoulder.\n* Acute or chronic osteomyelitis.\n* Inflammatory joint disease (rheumatoid arthritis\u002F (pseudo)gout arthritis).\n* Uncontrolled diabetes.\n* Active oncological disease.\n* Radiologically stage IV shoulder joint arthrosis (rotator cuff arthropathy).\n* Systemic or intra-articular corticosteroid therapy less than 60 days prior to planned operation date.\n* Intramuscular or peroral corticosteroid treatment less than 30 days prior to planned operation date.\n* Acute or chronic conditions that are contraindications for functional testing.\n* MRI contraindicated.\n* Substance or alcohol abuse.\n* Refusal or withdrawal of consent.","50 Years","80 Years",{"count":101,"type":20},80,[53],"Rotator cuff tear is the leading cause of shoulder pain in the elderly. There isn't enough evidence nor clinical guidelines to guide the treatment of massive rotator cuff tears, specially irreparable tears. Arthroscopic partial repair has been widely used and superior capsular reconstruction (SCR), either with allograft, autograft or augmentation with long head biceps brachii tendon (LHBBT), has been recently added. It is showing promising results, but lacking high quality evidence.\n\nThis is a prospective clinical study to compare the outcomes of different surgical methods for massive rotator cuff tendon tears. Minimal follow-up time will be two years. In this trial, massive rotator cuff tears will be anatomically repaired if possible. For irreparable tears a method will be randomly assigned intra-operatively once a tear is determined to be irreparable - either partial repair or partial repair with superior capsular reconstruction using the long head biceps brachii (LHBB) tendon. Patients who are eligible for the study but refuse operative treatment, will serve as conservative study group.\n\nThe hypothesis is that massive rotator cuff tears that are reparable will have the best functional outcomes. For irreparable tears, augmentation with LHBBT will give superior results over partial repair.",[105,106],"Rotator Cuff Tears","Rotator Cuff Syndrome",[108,109,110,111,112,113,114,115,116,117,118],"rotator cuff injury","rotator cuff tears","massive","shoulder","shoulder injuries","superior capsular reconstruction","long head of biceps tendon","irreparable","tear","rupture","partial repair","NOT_YET_RECRUITING","2023-11-22",{"date":122,"type":33},"2023-11-24",{"date":124,"type":20},"2024-01",{"date":126,"type":20},"2033-12",{"name":39,"class":40},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":51,"phases":139,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":90},"100424840","rct-comparing-oagb-and-long-limb-roux-gastric-bypass-100424840","NCT04812132","RCT Comparing OAGB and Long Limb Roux Gastric Bypass","A Multicentre Randomized Controlled Trial Comparing Outcome of Laparoscopic One-anastomosis Gastric Bypass and Laparoscopic Long Biliopancreatic Limb Roux Gastric Bypass for Treatment of Morbid Obesity.","OAGBvsLLbypass","Inclusion Criteria:\n\n* BMI over 35 and obesity related disease\n* BMI over 40\n* age between 18-60 years\n* agrees to participate in the study\n\nExclusion Criteria:\n\n* age under 18 years or over 60 years\n* abundant adhesions discovered during the surgery\n* active upper gastrointestinal ulcer disease\n* prior bariatric surgery\n* active symptomatic reflux disease\n* active psychiatric disease (eg psychosis)","60 Years",{"count":138,"type":20},500,[53],"A prospective multicenter randomized controlled trial to compare the outcomes of one-anastomosis gastric bypass to long biliary limb Roux gastric bypass.\n\nWe plan to enroll up to 500 patients from three different clinics in Estonia. Outcomes are excess weight loss %, impact on type 2 diabetes, hypertension, hyperlipidemia and obstructive sleep apnea.\n\nOther outcomes are nutritional deficiencies, occurrence of reflux disease and impact on quality of life.\n\nThere are planned outpatient visits 1, 5 and 10 years after the surgery to measure the impacts.\n\nThere are a lot of studies comparing OAGB to standard Roux gastric bypass but non comparing it to long biliary limb gastric bypass.",[142],"Obesity",[144,145,146,142],"OAGB","Long biliary limb Roux gastric bypass","Metabolic surgery","2021-03-21",{"date":149,"type":33},"2021-03-23",{"date":151,"type":33},"2021-01-01",{"date":153,"type":20},"2036-12-31",{"name":39,"class":40},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":164,"conditions":165,"keywords":168,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":90},"100321646","five-year-outcome-of-laparoscopic-gastric-sleeve-100321646","NCT03467581","Five-year Outcome of Laparoscopic Gastric Sleeve","Five-year Outcome of Laparoscopic Gastric Sleeve, Resolution of Comorbidities and Risk for Cumulative Nutritional Deficiencies.","Inclusion Criteria:\n\n* The criteria for bariatric surgery: BMI of \\>40, or \\>35 with certain obesity related comorbidities\n\nExclusion Criteria:\n\n* Patients who did not fill the inclusion criteria","65 Years",{"count":138,"type":20},"The aim of this study is to evaluate the long-term (5-year follow-up) results of laparoscopic gastric sleeve (LGS) in terms of weight loss and obesity related comorbidities, as well as the risk factors associated with postoperative nutritional deficiencies.",[166,167],"Bariatric Surgeries","Metabolic Surgery",[169],"gastric sleeve","2018-03-09",{"date":172,"type":33},"2018-03-16",{"date":174,"type":33},"2008-10-08",{"date":176,"type":20},"2028-12-31",{"name":39,"class":40},""]